OGX-011 gets on FDA “fast track”

OncoGenex Pharmaceuticals announced today that OGX-011 (custirsen sodium) received Fast Track designation from the U.S. Food & Drug Administration in combination with docetaxel for potential treatment of progressive metastatic prostate cancer. OGX-011 is currently completing Phase II clinical studies in prostate and other cancers. The drug is designed to inhibit the production of a specific protein, clusterin, associated with treatment resistance.

We had already reported on the available data from Phase II prostate cancer trials that were presented at the ASCO annual meeting earlier this year. Phase III trials can be expected to start in the relatively near future.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: